Chronic lymphocytic leukaemia trials in Japan
13 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Hiroshima, Izumo, Koto, Nagasaki, Nankoku, Osaka, Sakai, Sapporo, Yamagata
- Age
- 18 years and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - Phase 1Enrolling by invitationA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Nagoya, Tokyo
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 4Taking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Isehara
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - Phase 1/2Taking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Kōtoku, Matsuyama, Nagoya
- Age
- 18 years and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - Phase 3Taking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Chiba, Fukuoka, Hiroshima, Izumo, Kobe, Koto, Maebashi, Nagoya, Okayama, Osaka, Sakai, Sapporo, Sendai, Yamagata
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Chiba, Kashiwa, Kōtoku, Nagoya, Yokohama
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Chūōku, Kashiwa
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- AmagasakiCity, Bunkyoku, Chiba, Hirakata, Hiroshima, Kagoshima, Kawagoeshi, Kumamoto, Kurashikishi, KyotoShi, Matsuyama, Nagoya, Niigata, Okayama, Osaka, Sakai, Sapporo, Sendai, Shinagawaku
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - Phase 3Taking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bunkyoku, Fukushima, Hiroshima, Koshigaya, Kōtoku, Kumamoto, Kyotoshi, Matsuyama, Nagoya, Nakamuraku, Nankoku, Ōita, Okayama, Osaka, Sakai, Sapporo, Tachikawashi, Yamagata
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - Phase 3Taking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Kumamoto, Yamagata
- Age
- 18 years and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - Phase 4Taking peopleA Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Where
- Aichi-Ken, Cho-ku, Fukuoka, Isehara, Miyagi-Ken, Sapporo
- Age
- 18 years and over
- People
- 787 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06876649 - Phase 4Taking peopleA Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Where
- Aichi-Ken, Cho-ku, Fukuoka, Isehara, Miyagi-Ken, Sapporo
- Age
- 18 years and over
- People
- 279 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06876662 - No phaseTaking peopleTransgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Where
- Kumamoto, Toyokawa
- People
- 50 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06357754